13F HOLDINGS REPORT
Foresite Capital Management IV, LLC
Quarter ended Q3 2023 · Filed August 11, 2023 · Accession 0001104659-23-090055
Total Value
$203.4M
Positions
7
Other Managers
0
Confidential Omitted
No
Holdings (7)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | Pharvaris N.V. | PHVS | 3,743,450 | $56.7M | 27.86% |
| 2 | Lyell Immunopharma, Inc. | LYEL | 9,700,000 | $30.8M | 15.17% |
| 3 | Kinnate Biopharma Inc. | 49705R105 | 9,671,643 | $29.3M | 14.41% |
| 4 | Aclaris Therapeutics, Inc. | ACRS | 2,808,034 | $29.1M | 14.32% |
| 5 | Kura Oncology, Inc. | KURA | 1,849,947 | $19.6M | 9.62% |
| 6 | Cymabay Therapeutics, Inc. | 23257D103 | 1,787,094 | $19.6M | 9.62% |
| 7 | Syndax Pharmaceuticals, Inc. | SNDX | 875,000 | $18.3M | 9.00% |